Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2687-2693

  Shimizu, Kazutaka ^a   Taniyama, Yoshiaki ^a   Sanada, Fumihiro ^a   Azuma, Junya ^a   Iwabayashi, Masaaki ^a   Iekushi, Kazuma ^a   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Epithelial growth factor receptor; Hepatocyte growth factor; Lipopolysaccharide; Reactive oxygen species; Src homology domain 2 containing inositol 5' phosphatase 2

Indexed keywords

EPITHELIAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; INOSITOL 5' PHOSPHATASE; LIPOPOLYSACCHARIDE; PHOSPHATASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; EGFR PROTEIN, HUMAN; EGFR PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HGF PROTEIN, HUMAN; INOSITOL 1,4,5 TRISPHOSPHATE 5 PHOSPHATASE; INOSITOL-1,4,5-TRISPHOSPHATE 5-PHOSPHATASE; LIPOPOLYSACCHARIDE, E COLI O55 B5; LIPOPOLYSACCHARIDE, E COLI O55-B5; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SRC HOMOLOGY DOMAIN; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; AORTA; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; KIDNEY; LIVER; METABOLISM; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CAPILLARY PERMEABILITY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSFECTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84871884475     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300041     Document Type: Article

References (45)

1. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471-1477.
2. Danner R, Suffredini A, Natanson C, Parrillo J. Microbial Toxins: Role in the Pathogenesis of Septic Shock and Multiple Organ Failure. Fullerton, CA: Society of Crititical Care Medicine. 1989:151-192.
3. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. NEJM. 1993;328:1457-1460.
4. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol. 2005;3:36-46.
5. Gioannini TL, Weiss JP. Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res. 2007;39:249-260.
6. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 2007;19:3-10.
7. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994;179:269-277.
8. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999;189:1777-1782.
9. Miyake K. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol. 2004;12:186-192.
10. Crisostomo PR, Wang M, Herring CM, Markel TA, Meldrum KK, Lillemoe KD, Meldrum DR. Gender differences in injury induced mesen-chymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). J Mol Cell Cardiol. 2007;42:142-149.
11. Heo SK, Yun HJ, Noh EK, Park WH, Park SD. LPS induces infamma-tory responses in human aortic vascular smooth muscle cells via Tolllike receptor 4 expression and nitric oxide production. Immunol Lett. 2008;120:57-64.
12. Martich GD, Danner RL, Ceska M, Suffredini AF. Detection of inter-leukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinfammatory agents. J Exp Med. 1991;173:1021-1024.
13. Lin WN, Luo SF, Lee CW, Wang CC, Wang JS, Yang CM. Involvement of MAPKs and NF-kappaB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells. Cell Signal. 2007;19:1258-1267.
14. Lin WN, Luo SF, Wu CB, Lin CC, Yang CM. Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: involvement of Src/EGFR/PI3-K/Akt pathway. Toxicol Appl Pharmacol. 2008;228:256-268.
15. Lin FY, Chen YH, Chen YL, Wu TC, Li CY, Chen JW, Lin SJ. Ginkgo biloba extract inhibits endotoxin-induced human aortic smooth muscle cell proliferation via suppression of toll-like receptor 4 expression and NADPH oxidase activation. J Agric Food Chem. 2007;55: 1977-1984.
16. Huo Y, Qiu WY, Pan Q, Yao YF, Xing K, Lou MF. Reactive oxygen species (ROS) are essential mediators in epidermal growth factor (EGF)-stimulated corneal epithelial cell proliferation, adhesion, migration, and wound healing. Exp Eye Res. 2009;89:876-886.
17. Prasad NK, Decker SJ. SH2-containing 5′-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem. 2005;280:13129-13136.
18. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol. 2002;156:843-854.
19. Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene. 2005;24:2585-2588.
20. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature. 2002;416:183-187.
21. Nakamura T, Nawa K, Ichihara A. Partial purifcation and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122:1450-1459.
22. Russell WE, McGowan JA, Bucher NL. Partial characterization of a hepatocyte growth factor from rat platelets. J Cell Physiol. 1984;119:183-192.
23. Taniyama Y, Morishita R, Aoki M, Hiraoka K, Yamasaki K, Hashiya N, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Angiogenesis and antifbrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension. 2002;40:47-53.
24. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001;8:181-189.
25. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angio-genesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogen-esis in diabetes. Circulation. 2001;104:2344-2350.
26. Honda S, Kagoshima M, Wanaka A, Tohyama M, Matsumoto K, Nakamura T. Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res. 1995;32:197-210.
27. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997;276:60-66.
28. Koch A, Mancini A, El Bounkari O, Tamura T. The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene. 2005;24:3436-3447.
29. Sanada F, Taniyama Y, Iekushi K, Azuma J, Okayama K, Kusunoki H, Koibuchi N, Doi T, Aizawa Y, Morishita R. Negative action of hepato-cyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res. 2009;105:667-75, 13 p following 675.
30. Sanada F, Taniyama Y, Azuma J, Iekushi K, Dosaka N, Yokoi T, Koibuchi N, Kusunoki H, Aizawa Y, Morishita R. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension. 2009;53:77-82.
31. Iekushi K, Taniyama Y, Azuma J, Katsuragi N, Dosaka N, Sanada F, Koibuchi N, Nagao K, Ogihara T, Morishita R. Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin. Hypertension. 2007;49:1409-1414.
32. Orr AW, Stockton R, Simmers MB, Sanders JM, Sarembock IJ, Blackman BR, Schwartz MA. Matrix-specifc p21-activated kinase activation regulates vascular permeability in atherogenesis. J Cell Biol. 2007;176:719-727.
33. Bian K, Davis K, Kuret J, Binder L, Murad F. Nitrotyrosine formation with endotoxin-induced kidney injury detected by immunohistochemis-try. Am J Physiol. 1999;277(1 Pt 2):F33-F40.
34. Reutershan J, Basit A, Galkina EV, Ley K. Sequential recruitment of neu-trophils into lung and bronchoalveolar lavage fuid in LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;289:L807-L815.
35. Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol. 1998;275(3 Pt 1):G387-G392.
36. Chagnon F, Bentourkia M, Lecomte R, Lessard M, Lesur O. Endotoxin-induced heart dysfunction in rats: assessment of myocardial perfusion and permeability and the role of fuid resuscitation. Crit Care Med. 2006;34:127-133.
37. Cai Z, Pang Y, Lin S, Rhodes PG. Differential roles of tumor necrosis factor-alpha and interleukin-1 beta in lipopolysaccharide-induced brain injury in the neonatal rat. Brain Res. 2003;975:37-47.
38. Wiesel P, Patel AP, DiFonzo N, Marria PB, Sim CU, Pellacani A, Maemura K, LeBlanc BW, Marino K, Doerschuk CM, Yet SF, Lee ME, Perrella MA. Endotoxin-induced mortality is related to increased oxi-dative stress and end-organ dysfunction, not refractory hypotension, in heme oxygenase-1-defcient mice. Circulation. 2000;102:3015-3022.
39. Fujita M, Kuwano K, Kunitake R, Hagimoto N, Miyazaki H, Kaneko Y, Kawasaki M, Maeyama T, Hara N. Endothelial cell apoptosis in lipo-polysaccharide-induced lung injury in mice. Int Arch Allergy Immunol. 1998;117:202-208.
40. Min JK, Lee YM, Kim JH, Kim YM, Kim SW, Lee SY, Gho YS, Oh GT, Kwon YG. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res. 2005;96:300-307.
41. Koff JL, Shao MX, Ueki IF, Nadel JA. Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol. 2008;294: L1068-L1075.
42. Koff JL, Shao MX, Kim S, Ueki IF, Nadel JA. Pseudomonas lipopoly-saccharide accelerates wound repair via activation of a novel epithelial cell signaling cascade. J Immunol. 2006;177:8693-8700.
43. Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cyto-kine. Lancet. 1995;345:293-295.
44. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential contribution of a novel antifbrotic factor, hepatocyte growth factor, to prevention of myocardial fbrosis by angiotensin II blockade in cardio-myopathic hamsters. Circulation. 2000;102:246-252.
45. Azuma J, Taniyama Y, Takeya Y, Iekushi K, Aoki M, Dosaka N, Matsumoto K, Nakamura T, Ogihara T, Morishita R. Angiogenic and anti-fbrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther. 2006;13:1206-1213.